RESUMO
RESUMO Objetivo: Analisar o perfil clínico de pacientes em acompanhamento dermatológico encaminhados para avaliação oftalmológica. Métodos: A amostra foi composta de pacientes dermatológicos encaminhados para avaliação oftalmológica, nos anos de 2016 e de 2017. Estudou-se a concomitância de doenças dermatológicas com as afecções oftalmológicas por meio da coleta simultânea do histórico dermatológico (prontuários registrados com dados gerais e diagnóstico) e de dados da consulta oftalmológica após o encaminhamento. Resultados: Foram avaliados pela oftalmologia 224 pacientes, sendo 65% do sexo feminino, 80% caucasianos, com idade variando entre 1 mês e 85 anos. As situações cujo encaminhamento foi mais prevalente foram psoríase, lúpus, vitiligo e rosácea (18,3%, 13,8%, 12,9% e 10,7%, respectivamente). Fototerapia crônica e uso de hidroxicloroquina representaram 35,7% e 22,3% dos pacientes. Casos de neurofibromatose, micose fungoide, líquen plano, neoplasias de pele, atopias, pênfigo e esclerodermia também estiveram presentes. Cegueira legal foi detectada em 6%, e deficiências visuais ligadas a afecções dermatológicas foram verificadas em 16,5% dos casos. As alterações oculares mais prevalentes foram catarata (18,9%), blefarite (15,9%), pterígio (5,3%) e conjuntivite (5,3%). Conclusão: Encontrou-se elevada frequência de alterações oftalmológicas em uma população de pacientes com doenças dermatológicas. Assim, o estudo e a análise de manifestações oculares em pacientes dermatológicos podem auxiliar na detecção precoce e na prevenção de complicações.
ABSTRACT Objective: To analyze the clinical profile of patients under dermatological care and referred to ophthalmological evaluation. Methods: The sample comprised dermatology patients referred to ophthalmological evaluation in 2016 and 2017. The simultaneous occurrence of skin and ophthalmic diseases was studied, by collecting dermatological history (medical records containing general data and diagnosis) and ophthalmic consultation data following referral. Results: A total of 224 patients were assessed, 65% were female, 80% were white, and age varied between one month and 85 years. The conditions more often referred were psoriasis, lupus, vitiligo and rosacea (18.3%, 13.8%, 12.9% and 10.7%, respectively). Chronic phototherapy and use of hydroxychloroquine were observed in 35.7% and 22.3% of patients, respectively. Cases of neurofibromatosis, mycosis fungoides, lichen planus, skin cancer, atopic dermatitis, pemphigus and scleroderma were also reported. Legal blindness was detected in 6% and visual impairment related to skin conditions in 16.5% of patients. The most prevalent ocular changes were cataracts (18.9%), blepharitis (15.9%), pterygium (5.3%) and conjunctivitis (5.3%). Conclusion: A high frequency of ophthalmic changes in a population of dermatological patients was found. In this context, studying and analyzing ocular manifestations in dermatological patients could be useful in early detection and prevention of complications.
Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Lactente , Pré-Escolar , Criança , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Dermatopatias/complicações , Transtornos da Visão/etiologia , Oftalmopatias/etiologia , Encaminhamento e Consulta , Dermatopatias/diagnóstico , Dermatopatias/epidemiologia , Transtornos da Visão/diagnóstico , Transtornos da Visão/epidemiologia , Brasil , Prontuários Médicos , Prevalência , Estudos Transversais , Oftalmopatias/diagnóstico , Oftalmopatias/epidemiologia , Manifestações OcularesRESUMO
BACKGROUND: Pruritus is a common symptom in many skin diseases. Music interventions have demonstrated their efficacy in different symptoms or diseases such as pain, depression and anxiety. OBJECTIVE: To evaluate the effects of a music intervention on pruritus. PATIENTS AND METHODS: A randomized controlled trial was conducted from November 2018 to April 2019. Fifty inpatients with pruritus intensity ≥3/10 in various chronic skin diseases were randomized in a music group or an emollient group. The primary endpoint was the evolution of pruritus as measured by the Numerical Rating Scale before and one hour after the procedure. The secondary judgement criteria were the effects on patient anxiety, the impact of pruritus on the quality of life and patient satisfaction (NCT03701971). RESULTS: Fifty patients with chronic pruritus were included, 62% were male, and the average age was 60.7 years. The most common diseases were psoriasis (N = 10), atopic dermatitis (N = 8) and contact eczema (N = 6). The average ItchyQol score was 64.8/110, showing a significant impact on quality of life. The intensity of pruritus decreased more significantly in the music intervention group than in the emollient group: 2.3 (SD 2.1) and 1.2 (SD 1.7), respectively (P < 0.05). There was a decrease in anxiety in both groups, with no statistical significant difference between groups. Among patients who received the music intervention, 64% reported feeling an improvement, 91% would recommend the music intervention, and 64% would like to continue this practice. DISCUSSION: Pruritus management is complex and requires first-line aetiological treatment. Aetiological or symptomatic treatments do not always provide enough relief; it is useful to find other therapeutic options. The music intervention has shown interest in our study. Its repeated use over the long term will be interesting to evaluate. As in pain, music may work by activating inhibitory neural circuits. The use of music is a simple method to manage chronic pruritus.
Assuntos
Musicoterapia , Prurido/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Ansiedade/etiologia , Ansiedade/terapia , Doença Crônica , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Satisfação do Paciente , Estudos Prospectivos , Prurido/complicações , Prurido/psicologia , Qualidade de Vida , Índice de Gravidade de Doença , Dermatopatias/complicações , Adulto JovemRESUMO
Chronic pruritus (>6 week's duration) in the geriatric population (≥65 years old), is an increasing health care problem. The pathophysiologic predisposing factors are abnormalities of the epidermal barrier, immune system, and nervous system. Causes can be dichotomized into histaminergic and nonhistaminergic pruritus. Topical treatments are generally safe. Systemic treatments are chosen depending on the condition, comorbid diseases, and drug interactions. Treatment options are limited. Progress has been made in identifying itch-selective mediators over the last decade. Numerous new medications are currently undergoing clinical trials and they are anticipated to enter the clinics in the near future.
Assuntos
Envelhecimento/fisiologia , Antipruriginosos/uso terapêutico , Prurido/tratamento farmacológico , Prurido/fisiopatologia , Envelhecimento da Pele/fisiologia , Idoso , Idoso de 80 Anos ou mais , Antidepressivos/uso terapêutico , Inibidores de Calcineurina/uso terapêutico , Capsaicina/uso terapêutico , Colestase/complicações , Doença Crônica , Emolientes/uso terapêutico , Histamina/metabolismo , Antagonistas dos Receptores Histamínicos/uso terapêutico , Humanos , Falência Renal Crônica/complicações , Hepatopatias/complicações , Mentol/uso terapêutico , Doenças do Sistema Nervoso/complicações , Cuidados Paliativos , Síndromes Paraneoplásicas/complicações , Prurido/etiologia , Dermatopatias/complicações , Urticária/complicaçõesRESUMO
Vitamin D plays a key role in skeletal and cardiovascular disorders, cancers, central nervous system diseases, reproductive diseases, infections, and autoimmune and dermatological disorders. The two main sources of vitamin D are sun exposure and oral intake, including vitamin D supplementation and dietary intake. Multiple factors are linked to vitamin D status, such as Fitzpatrick skin type, sex, body mass index, physical activity, alcohol intake, and vitamin D receptor polymorphisms. Patients with photosensitive disorders tend to avoid sun exposure, and this practice, along with photoprotection, can put this category of patients at risk for vitamin D deficiency. Maintaining a vitamin D serum concentration within normal levels is warranted in atopic dermatitis, psoriasis, vitiligo, polymorphous light eruption, mycosis fungoides, alopecia areata, systemic lupus erythematosus, and melanoma patients. The potential determinants of vitamin D status, as well as the benefits and risks of vitamin D (with a special focus on the skin), will be discussed in this article.
Assuntos
Suplementos Nutricionais , Dermatopatias/tratamento farmacológico , Deficiência de Vitamina D/prevenção & controle , Vitamina D/uso terapêutico , Vitaminas/uso terapêutico , Humanos , Fatores de Risco , Pele/imunologia , Pele/metabolismo , Pele/efeitos da radiação , Dermatopatias/sangue , Dermatopatias/complicações , Dermatopatias/imunologia , Pigmentação da Pele/imunologia , Pigmentação da Pele/efeitos da radiação , Luz Solar/efeitos adversos , Vitamina D/sangue , Vitamina D/imunologia , Vitamina D/metabolismo , Deficiência de Vitamina D/sangue , Deficiência de Vitamina D/etiologia , Vitaminas/sangue , Vitaminas/imunologia , Vitaminas/metabolismoRESUMO
Antecedentes: La psoriasis es una enfermedad inmune crónica con manifestaciones dermatológicas y articulares. Puede presentarse a cualquier edad pero ocurre con mayor frecuencia en dos picos: 20-30 años y 50-60 años. Tiene un componente genético fuerte porque aproximadamente el 30% de los pacientes tienen un familiar de primer grado con la enfermedad, y sus hijos pueden de-sarrollar artritis psoriásica sin alteraciones cutáneas. El paciente experimenta pocos periodos de remisión espontanea.Caso clínico: Mujer de 39 años, ama de casa del casco rural de Tela, diagnosticada con psoriasis hace 7 años. Acude a consulta en buen estado general sin secuelas psicológicas, con lesión en placa localizada en codo derecho con área afectada del 4% y eritrodermia psoriásica que cubre la totalidad del abdomen en un 9% de la supericie corporal. Reiere mejoría con los productos naturales. Actualmente con sobrepeso (27 IMC) y con hipertensión sistólica aislada (140/82 mmHg) sugerente de ateroesclerosis. Discusión: Se deben tomar en cuenta los aspectos psico-sociales y metabólicos que afectan la calidad de vida de estos pacientes, para tratarlos de forma inte-gral con un grupo multidisciplinario. El médico general puede manejar la psoriasis en casos concretos como las placas localizadas ≤ 5% del BSA, en los cuales el tratamiento indicado es tópico con corticoesteroides de alta potencia como primera línea. Para todo lo demás, el paciente con psoriasis debe ser evaluado por un dermatólogo.
Assuntos
Humanos , Feminino , Adulto , Psoríase/diagnóstico , Dermatopatias/complicações , Corticosteroides/farmacologia , Dermatite Esfoliativa/complicaçõesRESUMO
PURPOSE: The purpose of this study was to estimate the risk and economic burden of peristomal skin complications (PSCs) in a large integrated healthcare system in the Midwestern United States. DESIGN: Retrospective cohort study. SUBJECTS AND SETTING: The sample comprised 128 patients; 40% (n = 51) underwent colostomy, 50% (n = 64) underwent ileostomy, and 10% (n = 13) underwent urostomy. Their average age was 60.6 ± 15.6 years at the time of ostomy surgery. METHODS: Using administrative data, we retrospectively identified all patients who underwent colostomy, ileostomy, or urostomy between January 1, 2008, and November 30, 2012. Trained medical abstractors then reviewed the clinical records of these persons to identify those with evidence of PSC within 90 days of ostomy surgery. We then examined levels of healthcare utilization and costs over a 120-day period, beginning with date of surgery, for patients with and without PSC, respectively. Our analyses were principally descriptive in nature. RESULTS: The study cohort comprised 128 patients who underwent ostomy surgery (colostomy, n = 51 [40%]; ileostomy, n = 64 [50%]; urostomy, n = 13 [10%]). Approximately one-third (36.7%) had evidence of a PSC in the 90-day period following surgery (urinary diversion, 7.7%; colostomy, 35.3%; ileostomy, 43.8%). The average time from surgery to PSC was 23.7 ± 20.5 days (mean ± SD). Patients with PSC had index admissions that averaged 21.5 days versus 13.9 days for those without these complications. Corresponding rates of hospital readmission within the 120-day period following surgery were 47% versus 33%, respectively. Total healthcare costs over 120 days were almost $80,000 higher for patients with PSCs. CONCLUSIONS: Approximately one-third of ostomy patients over a 5-year study period had evidence of PSCs within 90 days of surgery. Costs of care were substantially higher for patients with these complications.
Assuntos
Estomia/efeitos adversos , Complicações Pós-Operatórias/economia , Complicações Pós-Operatórias/etiologia , Dermatopatias/etiologia , Estomas Cirúrgicos/efeitos adversos , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Custos e Análise de Custo/estatística & dados numéricos , Feminino , Humanos , Ileostomia/efeitos adversos , Ileostomia/enfermagem , Ileostomia/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Meio-Oeste dos Estados Unidos , Estomia/enfermagem , Estomia/estatística & dados numéricos , Estudos Retrospectivos , Higiene da Pele/métodos , Higiene da Pele/normas , Higiene da Pele/estatística & dados numéricos , Dermatopatias/complicações , Estomas Cirúrgicos/estatística & dados numéricos , Derivação Urinária/efeitos adversos , Derivação Urinária/enfermagem , Derivação Urinária/estatística & dados numéricosAssuntos
Hemorragia/induzido quimicamente , Doenças da Unha/induzido quimicamente , Selênio/intoxicação , Dermatopatias/induzido quimicamente , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Doença Crônica , Feminino , Hemorragia/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Doenças da Unha/complicações , Dermatopatias/complicações , Adulto JovemRESUMO
ANTECEDENTES: La urticaria solar es una urticaria crónica inducible física clasificada también como fotodermatosis idiopática. El objetivo de este trabajo es definir las características fenotípicas y valorar su incidencia. MATERIAL Y MÉTODO: Estudio multicéntrico retrospectivo en el que recogen datos epidemiológicos, características clínicas, fotobiológicas, analíticas y terapéuticas. RESULTADOS: Se ha incluido a 224 pacientes procedentes de 9 Unidades de Fotobiología. La distribución por sexos correspondió a 141 mujeres y 83 varones con una edad media al diagnóstico de 37,9 ańos (rango 3-73). El 26,7% presentaba antecedentes de atopia, con la rinitis alérgica como la manifestación más frecuente (16,5%). Un 75,9% de los pacientes refería clínica solo en zonas fotoexpuestas. El espectro implicado con más frecuencia fue la luz visible aisladamente (31,7%). En el 21% la urticaria solar solo fue posible desencadenarla con luz natural. El tratamiento más empleado por los expertos fueron los antihistamínicos por vía oral (65,46%) seguido por diferentes modalidades de fototerapia (34%). La resolución completa se observó con mayor frecuencia en urticaria solar desencadenada exclusivamente por luz visible o luz natural, con diferencias estadísticamente significativas (p < 0,05) con respecto a otras longitudes de onda. No se observa un incremento de la incidencia anual. CONCLUSIONES: Presentamos la serie de urticaria solar más larga hasta ahora publicada. Las características epidemiológicas, clínicas y fotobiológicas confirman los datos ya conocidos, aunque en nuestra serie destaca un alto índice de fototest negativos. La reactividad exclusiva a luz visible o luz natural se asocia a mayores probabilidades de resolución. No se observa una tendencia al aumento en la incidencia anual
BACKGROUND: Solar urticaria is a chronic inducible urticaria also classified as an idiopathic dermatosis. The objective of this paper is to define the phenotypic characteristics of solar urticaria and to evaluate its incidence. Material and method. This was a retrospective multicenter study in which data were gathered on the epidemiology and clinical, photobiologic, laboratory, and therapeutic characteristics of solar urticaria. RESULTS: A total of 224 patients (141 women and 83 men) were included from 9 photobiology units. The mean age of the patients was 37.9 years (range, 3-73 years). A history of atopy was detected in 26.7%, and the most common presentation was allergic rhinitis (16.5%). Clinical signs were limited to sun-exposed areas in 75.9% of patients. The light spectrum most commonly implicated was visible light only (31.7%), and in 21% of cases it was only possible to trigger solar urticaria with natural light. The treatments most widely used by photobiology experts were oral antihistamines (65.46%), followed by different forms of phototherapy (34%). Complete resolution was observed most often in patients with solar urticaria triggered exclusively by visible or natural light, with statistically significant differences with respect to other wavelengths (P<.05). No increase in the annual incidence of solar urticaria was observed. CONCLUSIONS: We have presented the largest series of solar urticaria published to date. The epidemiological, clinical, and photobiologic findings confirm previously reported data, although there was a particularly high rate of negative phototests in our series. Reactivity exclusively to visible or natural light was associated with a higher probability of resolution. No increasing trend was observed in the annual incidence
Assuntos
Humanos , Masculino , Feminino , Adulto , Urticária/patologia , Dermatopatias/complicações , Dermatopatias/epidemiologia , Fotobiologia/métodos , Estudos Retrospectivos , ProbabilidadeRESUMO
Cutaneous plasmacytosis (CP) is an uncommon chronic disease of unknown aetiology, reported mainly in middle-aged patients of Asian descent. It is diagnosed by a constellation of physical, laboratory, radiological and histopathological findings. We report a patient with CP who demonstrated a favorable and promising response to mask-bath PUVA.
Assuntos
Metoxaleno/uso terapêutico , Terapia PUVA/métodos , Fármacos Fotossensibilizantes/uso terapêutico , Dermatopatias/tratamento farmacológico , Adulto , Banhos , Doença Crônica , Humanos , Hipergamaglobulinemia/complicações , Masculino , Dermatopatias/complicações , Dermatopatias/patologiaRESUMO
Itch is a common symptom in the elderly population over 65 years old, and is often a chronic condition lasting more than 6 weeks. As in all age groups, but especially in the elderly, there can be a significant effect on the general health status and quality of life, with impaired daily activities and lack of sleep, which can also lead in some cases to depression or anxiety. The cause of chronic itch in the elderly is often multifactorial due to physiological changes in the aging skin, including impaired skin barrier function, and also due to decline in immunological (immunosenescence), neurological, and psychological changes associated with age. Common causes of chronic pruritus in the aging skin include xerosis (dry skin), dermatological disorders (eczema, psoriasis, lichen planus), and systemic (renal, hepatic, endocrine), neurodegenerative, and psychological diseases. Comorbidities in the elderly population lead to polypharmacy, increasing the potential risk of drug side effects, which can result in causing or exacerbating itch in the elderly patient. It is essential to obtain a detailed history, including drugs, as well as a thorough clinical examination with appropriate subsequent investigations. Management of the elderly patient with chronic pruritus should include treatment with topical therapies such as emollients as well as other agents for symptomatic relief. Systemic therapies should be directed at any underlying cutaneous or systemic diseases. Often the cause of itch in the elderly cannot be found and some systemic treatments can be used for symptomatic control of the itch, including antihistamines, gabapentin, and selective antidepressants. A holistic approach needs to be taken on an individual basis to relieve chronic pruritus, as the management of itch in the elderly can be a challenge.
Assuntos
Antipruriginosos/uso terapêutico , Antagonistas dos Receptores Histamínicos/uso terapêutico , Prurido/terapia , Envelhecimento da Pele , Higiene da Pele , Dermatopatias/terapia , Terapia por Acupuntura , Administração Cutânea , Idoso , Idoso de 80 Anos ou mais , Anticonvulsivantes/uso terapêutico , Antidepressivos/uso terapêutico , Colestase/complicações , Colestase/diagnóstico , Colestase/terapia , Emolientes/uso terapêutico , Doenças Hematológicas/complicações , Doenças Hematológicas/diagnóstico , Doenças Hematológicas/terapia , Humanos , Hipotireoidismo/complicações , Hipotireoidismo/diagnóstico , Hipotireoidismo/tratamento farmacológico , Falência Renal Crônica/complicações , Falência Renal Crônica/terapia , Neoplasias/complicações , Neoplasias/diagnóstico , Neoplasias/terapia , Doenças do Sistema Nervoso/complicações , Doenças do Sistema Nervoso/diagnóstico , Doenças do Sistema Nervoso/terapia , Prurido/etiologia , Dermatopatias/complicações , Dermatopatias/diagnóstico , Terapia UltravioletaRESUMO
La dermatosis conocida como colagenosis perforante reactiva (CPR) es una lesión que se caracteriza por la eliminación transepidérmica del colágeno. Existen dos formas de presentación: la heredada y la adquirida. La forma adquirida se presenta en la edad adulta, principalmente en diabéticos con insuficiencia renal crónica. El ácido hialurónico es un glucosaminoglucano de alto peso molecular que se sintetiza en el sistema vacuolar de los fibroblastos y otras células, como son los queratinocitos, con ayuda de los factores de crecimiento y en otras citocinas. La sulfadiazina argéntica es un fármaco tópico de acción antiinfecciosa que se utiliza para prevenir y tratar las infecciones en heridas y quemaduras de grado II y III. Su acción se realiza sobre bacterias y hongos (AU)
The dermatosis known since reactive perforating collagenosis (RPC) is an injury that is characterized by the transepidermal elimination of the collagen. Two forms of presentation exist: the inherited one and the acquired one. The acquired form appears in the adult age, principally in diabetics with renal chronic insufficiency. The hyaluronic acid is a glycosaminoglycan of high place molecular weight that is synthesized in the system vacuolar of the fibroblasts and other cells, since they are the keratinocytes, with help of the factors of growth and in other cytokines. The argentic sulphadiazine is a hackneyed medicament of antiinfectious action that is in use for anticipating and treating the infections in wounds and burns of degree the II and IIIrd. His action realizes it on bacteria and fungi (AU)
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Ácido Hialurônico/uso terapêutico , Sulfadiazina/uso terapêutico , Dermatopatias/complicações , Dermatopatias/tratamento farmacológico , Dermatopatias/enfermagem , Cicatrização , Ceratose/complicações , Ceratose/enfermagem , Manejo da Dor/métodos , Manejo da Dor/enfermagem , Manejo da Dor , Terapia PUVA/enfermagem , Atenção Primária à SaúdeRESUMO
Since the introduction of biologics for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and psoriasis (Pso) an increased risk of tuberculosis (TB) reactivation in patients with latent tuberculosis infection (LTBI) has been recorded for anti-TNF agents, while a low or absent risk is associated with the non-anti-TNF targeted biologics. To reduce this risk several recommendation sets have been published over time, but in most of them the host-related risk, and the predisposing role to TB reactivation exerted by corticosteroids and by the traditional disease-modifying anti-rheumatic drugs has not been adequately addressed. Moreover, the management of the underlying disease, and the timing of biologic restarting in patients with TB occurrence have been rarely indicated. A multidisciplinary expert panel, the Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy (SAFEBIO), was constituted, and through a review of the literature, an evidence-based guidance for LTBI detection, identification of the individualized level of risk of TB reactivation, and practical management of patients with TB occurrence was formulated. The literature review confirmed a higher TB risk associated with monoclonal anti-TNF agents, a low risk for soluble receptor etanercept, and a low or absent risk for non-anti-TNF targeted biologics. Considering the TB reactivation risk associated with host demographic and clinical features, and previous or current non-biologic therapies, a low, intermediate, or high TB reactivation risk in the single patient was identified, thus driving the safest biologic choice. Moreover, based on the underlying disease activity measurement and the different TB risk associated with non-biologic and biologic therapies, practical indications for the treatment of RA, PsA, AS, and Pso in patients with TB occurrence, as well as the safest timing of biologic restarting, were provided.
Assuntos
Terapia Biológica , Tuberculose Latente/terapia , Dermatopatias/complicações , Artrite Reumatoide/complicações , Humanos , Tuberculose Latente/complicações , Tuberculose Latente/diagnóstico , Fatores de Risco , Fator de Necrose Tumoral alfa/antagonistas & inibidoresRESUMO
Radiation-induced morphea (RIM) is a rare and under-recognized skin complication of radiotherapy. It is commonly wrongly diagnosed as other dermatological conditions or malignancy because of similar clinical characteristics. This literature review analyses 66 cases that have been reported in the literature since 1989. The clinical appearance often includes pain and disfiguration of affected area, which may influence the patient's quality of life. There is no clear connection between the radiotherapy dose, the fractionation scheme, the use of a boost, age, the presence of other dermatological conditions or other connective tissue diseases and the occurrence of RIM. Its pathogenesis is still unclear, but several theories are proposed to explain this phenomenon. The available data suggest that the abnormally high secretion of some cytokines (interleukin 4, interleukin 5, transforming growth factor) induced by radiation causes an extensive fibrosis after an activation of fibroblasts. Histological confirmation is crucial in distinguishing RIM from similar-looking diseases, such as chronic radiation dermatitis, cancer recurrence, radiation, recall dermatitis, new carcinoma or cellulitis. There is no clear treatment regimen for this condition. Clinical outcome after therapy is often unsatisfactory. The commonly used methods and agents include: topical and systemic steroids, calcineurin inhibitors, systemic immunosuppressants including methotrexate, tacrolimus, heparin, hyaluronidase, phototherapy (UVA, UVA1, UVB, PUVA), systemic antibiotics, imiquimod, mycophenolate mofetil, photophoresis. The differential diagnosis is challenging and requires a multidisciplinary approach to avoid misdiagnosis and to plan appropriate treatment.